210 related articles for article (PubMed ID: 15194376)
1. Effect of donor-recipient cytomegalovirus serologic status on outcomes in simultaneous kidney-pancreas transplant recipients.
Stratta RJ; Alloway RR; Lo A; Hodge EE;
Transplant Proc; 2004 May; 36(4):1082-3. PubMed ID: 15194376
[TBL] [Abstract][Full Text] [Related]
2. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus infection in simultaneous pancreas-kidney transplantation.
Malaise J; Ricart MJ; Moreno A; Crespo M; Fernández-Cruz L; Van Ophem D; Squifflet JP;
Transplant Proc; 2005; 37(6):2848-50. PubMed ID: 16182830
[TBL] [Abstract][Full Text] [Related]
4. Multivariate analysis of the influence of donor and recipient cytomegalovirus sero-pairing on outcomes in simultaneous kidney-pancreas transplantation: the South-Eastern Organ Procurement Foundation Experience.
Stratta RJ; Thacker LR; Sundberg AK;
Transplant Proc; 2005 Mar; 37(2):1271-3. PubMed ID: 15848692
[TBL] [Abstract][Full Text] [Related]
5. Risk factors and outcomes analyses at 36 months of a prospective, randomized, multicenter, trial of daclizumab induction in simultaneous kidney-pancreas transplant recipients.
Stratta RJ; Alloway RR; Lo A; Hodge EE
Transplant Proc; 2005 Oct; 37(8):3527-30. PubMed ID: 16298650
[TBL] [Abstract][Full Text] [Related]
6. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study.
Stratta RJ; Alloway RR; Lo A; Hodge E
Transplantation; 2003 Apr; 75(8):1260-6. PubMed ID: 12717213
[TBL] [Abstract][Full Text] [Related]
7. The impact of delayed graft function of the kidney on the pancreas allograft in simultaneous kidney-pancreas transplantation.
Reddy KS; Stratta RJ; Alloway RR; Lo A; Hodge EE;
Transplant Proc; 2004 May; 36(4):1078-9. PubMed ID: 15194374
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors for cytomegalovirus infection after orthotopic liver transplantation using an ultrasensitive polymerase chain reaction assay.
Basse G; Esposito L; Mengelle C; Kamar N; Ribes D; Lavayssière L; Pillet A; Suc B; Barange K; Rostaing L
Transplant Proc; 2006 Sep; 38(7):2339-41. PubMed ID: 16980084
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology of cytomegalovirus infection after pancreas transplantation.
Parsaik AK; Bhalla T; Dong M; Rostambeigi N; Dierkhising RA; Dean P; Abraham R; Prieto M; Kremers WK; Razonable RR; Kudva YC
Transplantation; 2011 Nov; 92(9):1044-50. PubMed ID: 21904269
[TBL] [Abstract][Full Text] [Related]
10. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
Lo A; Stratta RJ; Egidi MF; Shokouh-Amiri MH; Grewal HP; Kisilisik AT; Trofe J; Alloway RR; Gaber LW; Gaber AO
Transpl Infect Dis; 2001 Mar; 3(1):8-15. PubMed ID: 11429034
[TBL] [Abstract][Full Text] [Related]
11. Cytomegalovirus antibody status and kidney transplantation.
Terasaki PI; Yuge J; Cecka JM; Gjertson DW
Clin Transpl; 1994; ():509-18. PubMed ID: 7547579
[TBL] [Abstract][Full Text] [Related]
12. Gancyclovir prophylaxis in high risk patients.
Campino A
Transplant Proc; 2005 Dec; 37(10):4311-2. PubMed ID: 16387106
[TBL] [Abstract][Full Text] [Related]
13. Cytomegalovirus infection in kidney transplant recipients: Evolution of approach through three eras.
Boucher A; Lord H; Collette S; Morin M; Dandavino R
Transplant Proc; 2006 Dec; 38(10):3506-8. PubMed ID: 17175316
[TBL] [Abstract][Full Text] [Related]
14. One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative dosing regimen of daclizumab.
Stratta RJ; Alloway RR; Lo A; Hodge EE;
Transplant Proc; 2004 May; 36(4):1080-1. PubMed ID: 15194375
[TBL] [Abstract][Full Text] [Related]
15. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis.
Rayes N; Seehofer D; Kahl A; Kokott S; Pratschke J; Frei U; Neuhaus P
Transpl Int; 2007 Nov; 20(11):974-81. PubMed ID: 17680782
[TBL] [Abstract][Full Text] [Related]
17. The impact of pretransplant cytomegalovirus infection on acute renal allograft rejection.
Chen JH; Mao YY; He Q; Wu JY; Lv R
Transplant Proc; 2005 Dec; 37(10):4203-7. PubMed ID: 16387078
[TBL] [Abstract][Full Text] [Related]
18. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
[TBL] [Abstract][Full Text] [Related]
19. A multicenter analysis of the significance of HLA matching on outcomes after kidney-pancreas transplantation.
Lo A; Stratta RJ; Alloway RR; Hodge EE;
Transplant Proc; 2005 Mar; 37(2):1289-90. PubMed ID: 15848699
[TBL] [Abstract][Full Text] [Related]
20. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.
Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S
Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
